Simplex Trading
PMCB icon

Simplex Trading’s PharmaCyte Biotech PMCB Stock Holding History

Simplex Trading’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231 Hold
12,400
– – ﹤0.01% 9047
2026
Q1 		$8.25K Hold
12,400
– – ﹤0.01% 7511
2025
Q4 		$8.98K Buy
+12,400
New +$11.2K ﹤0.01% 7059
2023
Q1 		– Sell
-74,200
Closed -$217K – 9875
2022
Q4 		$217K Sell
74,200
-700
-0.9% -$2K ﹤0.01% 4130
2022
Q3 		$179K Buy
74,900
+62,000
+481% +$157K ﹤0.01% 4762
2022
Q2 		$28K Buy
12,900
+1,300
+11% +$2.84K ﹤0.01% 7226
2022
Q1 		$26K Buy
11,600
+3,100
+36% +$6.89K ﹤0.01% 7942
2021
Q4 		$21K Buy
+8,500
New +$23.4K ﹤0.01% 8318

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Simplex Trading's PMCB Position: Q2 2026 in Review

Simplex Trading sold out of PharmaCyte Biotech (PMCB) in Q2 2026, closing a stake of 19,940 shares — an estimated $15K sold.

Simplex Trading first reported a position in PMCB in Q2 2022 and held it in 9 quarters. The position peaked at $387K in Q1 2023. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Simplex Trading reported no remaining PharmaCyte Biotech position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 19,940 PharmaCyte Biotech shares in Q2 2026, an estimated $15K.
  • Simplex Trading first reported a position in PharmaCyte Biotech in Q2 2022 and held it in 9 quarters.
  • Simplex Trading's PharmaCyte Biotech position peaked at $387K in Q1 2023.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.